Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Colorectal Neoplasms 2Stomach Neoplasms 1Sarcoma 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Neoplasms 1Mesothelioma 1Major Advanced Solid Tumors Other Than Colorectal 1Glioblastoma 1Gastrointestinal Malignancies 1Gastro-enteropancreatic neuroendocrine tumor 1Endometrial Neoplasms 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms 1

Interventions

Gemcitabine 685130-nm albumin-bound paclitaxel 199Fluorouracil 190Oxaliplatin 177Albumin-Bound Paclitaxel 154Capecitabine 137Leucovorin 133Irinotecan 114Radiotherapy 96Taxes 85pembrolizumab 81Cisplatin 73Erlotinib Hydrochloride 70Radiosurgery 69Nivolumab 56Drug Therapy 56Bevacizumab 54Magnetic Resonance Spectroscopy 51Cyclophosphamide 50folfirinox 45Specimen Handling 43Docetaxel 42Cetuximab 40Biopsy 39irinotecan sucrosofate 38S 1 (combination) 36Pancreaticoduodenectomy 35Blood Specimen Collection 34Surgical Procedures, Operative 31Paclitaxel 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × PM 01183 × Gastrointestinal × Clear all
NCT02210364 2016-12-14

Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC).

PharmaMar

Phase 1 Completed
81 enrolled
BreastGastrointestinal

Breast Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡